Shenwan Hongyuan Securities·2026-03-30 08:31Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook compared to the overall market performance [56]. Core Insights - The report highlights that 2025 will see concentrated performance releases across the overseas pharmaceutical sector, with companies like Kelun-Biotech, WuXi AppTec, and Fuhong Hanlin showing significant revenue growth and expanding product pipelines [2][12][15]. - Kelun-Biotech's revenue increased by 6.5% to 2.06 billion CNY, while its product sales surged by 949.8% to 543 million CNY, indicating strong market traction [7][8]. - WuXi AppTec reported a robust revenue growth of 46.7% to 5.94 billion CNY, driven by increased capacity utilization and operational efficiency [12][13]. - Fuhong Hanlin's revenue grew by 16.5% to 6.67 billion CNY, with a notable increase in R&D expenses, reflecting a commitment to innovation [15][16]. Summary by Sections Overseas Pharmaceuticals - The report notes that the Hang Seng Healthcare Index fell by 3.23%, underperforming the Hang Seng Index by 0.70 percentage points [6]. - Kelun-Biotech's core pipeline, Sac-TMT, is progressing well overseas, with multiple key clinical trials initiated [9][10]. - WuXi AppTec's market share increased from 21.7% in 2024 to over 24% in 2025, with a significant rise in unfulfilled orders [13][14]. Fuhong Hanlin - Fuhong Hanlin's global product revenue reached 5.82 billion CNY, with overseas sales exceeding 2 billion CNY, reflecting a strong international presence [15][16]. - The company is actively advancing clinical development for its innovative products, including HLX43 and HLX22, which target various cancers [16][17]. Investment Recommendations - The report suggests focusing on companies like Kelun-Biotech and WuXi AppTec due to their strong growth trajectories and expanding product lines [29]. - It also highlights the potential of Fuhong Hanlin's innovative pipeline and its commitment to R&D as key factors for future growth [15][16].